Cyclacel Pharma 8-K: Common Stock Registered Under Exchange Act

Ticker: BGMSP · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1130166

Complexity: simple

Sentiment: neutral

Topics: regulatory-compliance, form-8k, corporate-governance

TL;DR

**Cyclacel Pharma filed an 8-K confirming its common stock is registered, signaling ongoing compliance and potential corporate communications.**

AI Summary

Cyclacel Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose that its Common Stock, with a par value of $0.001 per share, is registered on an exchange pursuant to Section 12(b) of the Securities Exchange Act of 1934. This filing also indicates the company's intent to satisfy obligations under Rule 425, Rule 14a-12, Rule 14d-2(b), and Rule 13e-4(c). For investors, this matters because it confirms the company's continued compliance with listing requirements and its intention to potentially engage in communications related to corporate actions, which could impact stock value.

Why It Matters

This filing confirms Cyclacel Pharmaceuticals' compliance with SEC regulations regarding its common stock, which is fundamental for maintaining its public listing and investor confidence.

Risk Assessment

Risk Level: low — This filing is routine and indicates compliance with regulatory requirements, posing minimal risk.

Analyst Insight

A smart investor would view this as a routine compliance filing, indicating no immediate material change to the company's operations or financial health, but would monitor for subsequent filings related to the rules mentioned (e.g., Rule 425 for communications related to business combinations).

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the purpose of Cyclacel Pharmaceuticals, Inc.'s 8-K filing dated January 8, 2024?

The primary purpose of Cyclacel Pharmaceuticals, Inc.'s 8-K filing on January 8, 2024, is to report that its Common Stock, with a par value of $0.001 per share, is registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.

Which specific SEC rules does Cyclacel Pharmaceuticals, Inc. intend to satisfy with this 8-K filing?

Cyclacel Pharmaceuticals, Inc. intends for this 8-K filing to simultaneously satisfy the filing obligations under Rule 425 (17 CFR 230.425), Rule 14a-12 (17 CFR 240.14a-12), Rule 14d-2(b) (17 CFR 240.14d-2(b)), and Rule 13e-4(c) (17 CFR 240.13e-4(c)).

What is the par value of Cyclacel Pharmaceuticals, Inc.'s Common Stock mentioned in the filing?

The par value of Cyclacel Pharmaceuticals, Inc.'s Common Stock mentioned in the filing is $0.001 per share.

What is the registrant's telephone number and business address as stated in the filing?

The registrant's telephone number is (908) 517-7330, and its business address is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.

Under which section of the Securities Exchange Act of 1934 is Cyclacel Pharmaceuticals, Inc.'s Common Stock registered?

Cyclacel Pharmaceuticals, Inc.'s Common Stock is registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.

Filing Stats: 671 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-01-08 17:45:45

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Cyclacel Pharmaceuticals, Inc. (the "Company") provided an update for investors at the Biotech Showcase 2024 Conference in San Francisco, California, presenting information relating to certain strategic and business updates (the "Investor Presentation"), which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. A copy of the Investor Presentation will also be accessible on the Company's website at www.cyclacel.com, in the "Presentations & Events" subsection of the "Investors" tab. Cautionary Note Regarding Forward-Looking cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the Investor Presentation regarding these forward-looking statements. The information in Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration except as shall be expressly set forth by specific reference in such filing. In addition, the contents of the Company's website are not incorporated by reference into this Current Report on Form 8-K and you should not consider information provided on the Company's website to be part of this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished herewith: 99.1 Cyclacel Pharmaceuticals, Inc. Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: January 8, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing